Fibrocystic Breast
|
Wobenzym® is very effective therapy for the management of
fibrocystic breast disease, especially since it does not
interfere with already upset hormonal balance that typically
accompanies fibrocystic breast disease. From FREQUENTLY ASKED QUESTIONS, with answers by Joseph J Collins, RN, ND Read the special section: HORMONES & WOBENZYM® |
What the literature says about Systemic Enzyme Support and:
Fibrocystic Breast Disease
Wobenzym in therapy of various forms of fibrocystic disease with
individually selected immunomodulators.
Loginova N.S., Naumkina N.G., Sukhikh G.T. Wobenzym in therapy of
various forms of fibrocystic disease with individually selected
immunomodulators. International congress "Advances in Immunology and
Allergology at the Treshold of the XXI Century" May 3-6, 2000, Eilat,
Israel
Cancer of mammary glands is known to be registered 3-5 times more
often in patients with fibrocystic disease (FCD), the risk increases
30 times as much in the signs of proliferation. We elaborated
therapy regimen for patients with FCD by means of Wobenzym having
antiinflammatory, immunomodulating effect.
Immunomodulators were selected individually for every patient under
the control of interferon status (IFS): Cycloferon, Ridostin,
Polyoxidony. The treatment was performed in 36 women, aged from 23
to 52, having various forms of FCD: diffuse FCD: 1. multiple large
filled cysts, 1.5-5.5 cm in diameter; 2. small cystic component
prevailing; 3. glandular component prevailing. To assess the dynamic
control of the quality of the therapy, we used radiothermometric
method based on the measurement of internal temperature area (focal
thermoassymetry).
Before the therapy, decreased abilities of lymphocytes to produce a
-g -IFN had been noted, elevated level of serum IFN was found in
blood. After the treatment, 87.3% patients had the restored ability
of lymphocytes to produce a -g -IFN with the improved clinical
picture, similar results were found in 23.4% of patients which
underwent only basic therapy. Thus, Wobenzym is most efficient in
combination with Cycloferon in the treatment of patients with
mastopathy with small cystic, fibrous and glandular component
prevailing.
Enzyme therapy in treatment of mastopathy. A randomized double-blind
clinical study.
Rammer E, Friedrich F. Enzyme therapy in treatment of mastopathy. A
randomized double-blind clinical
In
this randomized double-blind clinical study the efficacy of an
enzymepreparation (Wobenzym) was compared with hormone therapy (Lynestrenol)
in 29women with mastopathy. There was a significantly greater
decrease in number ofhardenings of the mammary gland after 2 months
of enzyme therapy than Lynestrenoltherapy: improvement in the former
group was 100%, in the latter group 78.6%. No significant difference
was observed regarding the numbers of lumps, or number andsize of
cysts, sensitivity to touch, feeling of tension, spontaneous pain,
andpain on pressure. The efficacy of both medicines is valued as
good. Wobenzymtherapy was tolerated very well. No side effects
appeared at all. Enzyme therapy is an alternative, low-risk therapy
for the management of mastopathy, which does not interfere with the
already upset hormonal balance of the patients.
External Link:
PMID: 8650928
Treatment of fibrocystic mastopathy with hydrolytic enzymes.
F.-W. Dittmar1, W. Luh2. Treatment of
fibrocystic mastopathy with hydrolytic enzymes. International J. of
Experimental and Clinical Chemotherapie 1993: Vol. 6, No. 1, pp.
9-20. WE 13 (5-03-1) = WE 49 (5-04-1) nìm.
Abstract: Fibrocystic mastopathy affects about 50 % of all women in
the course of their lives. Because of subjective symptoms, the risk
of malignant degeneration (5 % of all cases), and ensuing physical
and psychological stress, treatment of fibrocystic mastopathy is
indispensable. So far, there is no causal therapy. Most common
therapeutical regimens are associated with severe side
effects.Therefore, the effect of treatment with an enzyme
combination preparation was compared with that of placebo in a
randomized double blind study in 96 patients with mastopathy over a
study period of 6 weeks.
At
the start of the study both groups were well comparable with respect
to all relevant study parameters. At the end of the study period
there were significant differences regarding the parameters of
effectiveness "diameter of the largest cyst" (p = 0.003),
"subjective disturbance by symptoms" (p = 0.001) and "cumulative
score of complaints" (p < 0.001). As far as the number of cysts is
concerned, there was no significant difference at the end of the
study period (p = 0.695). Bearing in mind, however, that the initial
condition was somewhat worse in the group treated with enzymes, a
tendency towards better effectiveness of the enzyme combination
preparation was observed with respect to this criterion, too. The
difference of absolute change was significant (p = 0.008). The
assessment of effectiveness by physician and patient showed clear
advantages of the enzyme therapy over placebo.
There was a higher number of mostly mild side effects in the enzyme
group, but only stomach complaints and loose stool. Since tolerance
was also comparable with that of placebo, the results obtained lead
to the conclusion that the enzyme combination preparation lends
itself to the symptomatic treatment of fibrocystic mastopathy.
Further longer-term studies, including biopsies and determination of
hormonal parameters, will clarify whether causal treatment of
fibrocystic mastopathy is possible.
Key
words: Fibrocystic mastopathy - enzyme therapy - enzyme combination
preparation vs. placebo
Poster Reference Number 26.